Literature DB >> 9563369

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids.

H Derendorf1, G Hochhaus, B Meibohm, H Möllmann, J Barth.   

Abstract

There are significant differences in the pharmacokinetic properties of inhaled corticosteroids currently used in medical practice. All are rapidly cleared from the body but they show varying levels of oral bioavailability and more importantly variation in the rate of absorption after inhalation. Oral bioavailability is lowest for fluticasone propionate, indicating a low potential for unwanted systemic corticosteroid effects. Mathematical modeling has shown pulmonary residence times to be longest for fluticasone propionate and triamcinolone acetonide but shortest for budesonide and flunisolide. These properties appear to relate to pulmonary solubility, which appears to be the rate-limiting step in the absorption process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563369     DOI: 10.1016/s0091-6749(98)70156-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  38 in total

1.  Methods to determine lung distribution of inhaled drugs - could gamma scintigraphy be the gold standard?

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

3.  Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.

Authors:  C Minto; B Li; B Tattam; K Brown; J P Seale; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 4.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

5.  Inhaled corticosteroids and the risk of diabetes among the elderly.

Authors:  Nandini Dendukuri; Lucie Blais; Jacques LeLorier
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

6.  Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.

Authors:  Noureddine Hamitouche; Emmanuelle Comets; Mégane Ribot; Jean-Claude Alvarez; Eric Bellissant; Bruno Laviolle
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

Review 7.  Very high dose inhaled corticosteroids: panacea or poison?

Authors:  G Russell
Journal:  Arch Dis Child       Date:  2006-10       Impact factor: 3.791

8.  Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients.

Authors:  Nina Kim; Thomas H Thatcher; Patricia J Sime; Richard P Phipps
Journal:  JCI Insight       Date:  2017-02-09

Review 9.  Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

Authors:  H M Lamb; C R Culy; D Faulds
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 10.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.